
| | | |
|------------------------------|---|----------------------------|
| STATE OF WISCONSIN, |) | |
| |) | |
| Plaintiff, |) | |
| |) | |
| v. |) | Case No. 04-CV-1709 |
| |) | |
| ABBOTT LABORATORIES, ET AL., |) | |
| |) | |
| Defendants. |) | |

**ROXANE LABORATORIES, INC. AND BOEHRINGER INGELHEIM ROXANE, INC.’S
RESPONSES AND OBJECTIONS TO PLAINTIFF’S SEVENTH SET OF REQUESTS
FOR PRODUCTION OF DOCUMENTS**

Pursuant to Wis. Stat. § 804.09, Boehringer Ingelheim Roxane, Inc. and Roxane Laboratories, Inc. (collectively “Roxane”) object and respond to Plaintiff State of Wisconsin’s Seventh Set of Requests for Production of Documents as follows:

PRELIMINARY STATEMENT

1. In April 2005, Roxane Laboratories, Inc., a Delaware corporation, changed its name to Boehringer Ingelheim Roxane, Inc. (“BIRI”). BIRI remains a Delaware corporation. BIRI continues to manufacture pharmaceutical products. Also in April 2005, a new corporation, Roxane Laboratories, Inc. a Nevada corporation was created. As of that time, the new Nevada corporation (“RLI Nevada”) assumed responsibilities for sales and marketing of multi-source pharmaceutical products sold under the Roxane tradename. Because the focus of Plaintiff’s Requests is on the sale and marketing of Roxane products, for the purpose of these answers and objections to the Requests, all responses regarding the time period before April, 2005 will be made by BIRI while all responses after April 2005 will be made by RLI Nevada.

2. As to all matters referred to in these answers and objections to the Requests, Roxane’s investigation and discovery continues. The specific responses set forth below, and any

production made consistent with the accompanying Requests, are based upon, and necessarily limited by, information now available to Roxane. Roxane reserves the right to modify or supplement these responses and objections, to raise any additional objections deemed necessary and appropriate in light of the results of any further review, and to present in any proceeding and at trial any further information and documents obtained during discovery and preparation for trial.

RESPONSES TO REQUESTS

DOCUMENT REQUEST NO. 22: All documents relating to your purchase, license, or receipt, of pricing information, including but not limited to average wholesale prices (“AWPs”) or wholesale acquisition costs (“WACs”) from First DataBank, Red Book, or Medispan for your drugs or the drugs of your competitors, including but not limited to contracts or license agreements. This request includes, but is not limited to, your purchase, license, or receipt of First DataBank’s National Drug Data File (“NDDF”). In addition, this request includes, but is not limited to contracts or license agreements between you and any other party that provides pricing information from First DataBank, Red Book, or Medispan (for example, agreements between you and DMD America in connection with its “Analysource” product).

RESPONSE TO REQUEST NO. 22: In addition to the general objections set forth below, Roxane objects to Document Request No. 22 on the grounds that it is overly broad and the following terms or phrases are vague, ambiguous and undefined: “any other party that provides” and “pricing information.” Roxane further objects to this Request to the extent it seeks documents that are neither relevant to the State’s claims nor reasonably calculated to lead to the discovery of admissible evidence.

Subject to and without waiving its general and specific objections, Roxane states it will make available for inspection and/or copying non-privileged responsive documents, to the extent that such documents exist.

GENERAL OBJECTIONS

1. Roxane incorporates by reference all of its general objections enumerated in Roxane Laboratories, Inc. and Boehringer Ingelheim Roxane, Inc.'s Responses and Objections to Plaintiff's Fifth Set of Requests for Production of Documents, served on Plaintiff July 27, 2007, as part of its response to each request set forth above.

Dated: March 5, 2008

Respectfully submitted,

/s/ Ceylan Ayasli Eatherton

Helen E. Witt, P.C.

Brian P. Kavanaugh

Elizabeth S. Hess

Ceylan Ayasli Eatherton

Kirkland & Ellis LLP

200 East Randolph Drive

Chicago, Illinois 60601

Tel: (312) 861-2000

Fax: (312) 861-2200

Mr. Patrick J. Knight

Gimbel Reilly Guerin & Brown

Two Plaza East, Suite 1170

330 East Kilbourn Avenue

Milwaukee, WI 53202

Tel: (614) 464-6400

Fax: (614) 464-6350

*Attorneys for Defendants Boehringer
Ingelheim Roxane, Inc. and Roxane
Laboratories, Inc.*

CERTIFICATE OF SERVICE

I, Ceylan Ayasli Eatherton, hereby certify that on this 5th day of March, 2008, a true and correct copy of the foregoing ROXANE LABORATORIES, INC. AND BOEHRINGER INGELHEIM ROXANE, INC.'S RESPONSES AND OBJECTIONS TO PLAINTIFF'S SEVENTH SET OF REQUESTS FOR PRODUCTION OF DOCUMENTS was served on all counsel of record via Lexis Nexis File & Serve®.

/s/ Ceylan Ayasli Eatherton
Ceylan Ayasli Eatherton